Back to Results
First PageMeta Content
Combination drugs / Asthma / Phenethylamines / Salmeterol / Phenols / GlaxoSmithKline / Fluticasone/salmeterol / Formoterol / Budesonide/formoterol / Medicine / Pulmonology / Respiratory therapy


Discussion of benefits in the context of risks of LABAs for the treatment of asthma
Add to Reading List

Document Date: 2009-01-05 11:05:20

Open Document

File Size: 256,54 KB

Share Result on Facebook

Country

United Kingdom / United States / /

MedicalCondition

MS / Asthma Ann W. McMahon / asthma / *Asthma / /

OperatingSystem

OSE / /

Organization

FDA / ND ND / Surveillance and Epidemiology Long-Acting Beta-Agonist Advisory Committee / office of Surveillance / /

Person

Ann W. McMahon / Ann Intern Med / /

Position

Acting Director / Division of Pharmacovigilance / Asthma First author / Dorinsky PM / Study Group / SNS1 General / /

Product

Advair HFA / Advair Diskus / Foradil Certihaler / Symbicort / Beta-2 / Serevent / Foradil / /

SocialTag